James is a National Heart Foundation Future Leader Fellow and Team Leader of Muscle Signalling at the Murdoch Children's Research Institute. His research focuses on uncovering the molecular mechanisms of genetic cardiomyopathies and developing precision therapies to treat these debilitating conditions.

Dr. Melissa Reichelt is a tenured teaching and research academic in the School of Biomedical Sciences at The University of Queensland and Co-Director of the Centre for Cardiovascular Health and Research. She leads the Cardiac Disease and Therapy Group, which focuses on optimising heart function in clinically relevant models of cardiovascular disease, including chronic hypertension, myocardial ischemia, diabetes, ageing, and cancer therapy–related cardiotoxicity. Her research spans multiple levels of cardiac investigation, from single-cell populations and isolated heart function to whole-heart physiology. This work is integrated with advanced gene-editing approaches to precisely target specific cardiac cell subtypes, enabling modification of receptor expression and function in a time- and cell-specific manner. These innovative strategies for gene-based interventions hold significant potential for treating heart disease and are a major focus of her group’s ongoing research.

Dr Kizana is a clinician/researcher at the Westmead Research Hub who divides his time between clinical cardiac electrophysiology and translational research. Dr Kizana is Co-Director of the Centre for Heart Research and Cardiac Gene Therapy Group Leader at the Westmead Institute for Medical Research, The University of Sydney. To dovetail his clinical and research activities, he leads a research group focused on the development novel therapies for cardiac disease. The group are developing AAV vectors as a platform technology for targeting human myocardium and using these in preclinical models of human disease to advance gene therapy for heart disease.

Dr Kizana is a clinician/researcher at the Westmead Research Hub who divides his time between clinical cardiac electrophysiology and translational research. Dr Kizana is Co-Director of the Centre for Heart Research and Cardiac Gene Therapy Group Leader at the Westmead Institute for Medical Research, The University of Sydney. To dovetail his clinical and research activities, he leads a research group focused on the development novel therapies for cardiac disease. The group are developing AAV vectors as a platform technology for targeting human myocardium and using these in preclinical models of human disease to advance gene therapy for heart disease.

James is a National Heart Foundation Future Leader Fellow and Team Leader of Muscle Signalling at the Murdoch Children's Research Institute. His research focuses on uncovering the molecular mechanisms of genetic cardiomyopathies and developing precision therapies to treat these debilitating conditions.